- 专利标题： Dosage regimes for the administration of an anti-CD25 ADC
-
申请号： US16622663申请日： 2018-06-14
-
公开(公告)号： US11426467B2公开(公告)日： 2022-08-30
- 发明人: Jay Marshall Feingold , Jens Wuerthner
- 申请人： ADC THERAPEUTICS SA , MEDIMMUNE LIMITED
- 申请人地址： CH Epalinges; GB Cambridge
- 专利权人： ADC THERAPEUTICS SA,MEDIMMUNE LIMITED
- 当前专利权人： ADC THERAPEUTICS SA,MEDIMMUNE LIMITED
- 当前专利权人地址： CH Epalinges; GB Cambridge
- 代理机构： Medler, Ferro, Woodhouse & Mills PLLC
- 优先权： GB1709439 20170614,GB1709441 20170614,GB1710493 20170630,GB1710496 20170630,GB1720541 20171208,GB1720544 20171208,GB1803298 20180228
- 国际申请： PCT/EP2018/065862 WO 20180614
- 国际公布： WO2018/229218 WO 20181220
- 主分类号： A61K47/68
- IPC分类号： A61K47/68 ; A61K47/54 ; A61P35/00 ; A61K31/5517 ; A61K39/395 ; A61K45/06 ; A61K39/00
摘要：
The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCS).